|
Roche and Spark Therapeutics, Inc. announce extension of tender offer
|
09 December 2019 |
|
FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
|
27 November 2019 |
|
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
|
13 September 2019 |
|
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
|
10 September 2019 |
|
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
|
03 September 2019 |
|
Roche's first FDA-approved tumour-agnostic medicine
|
16 August 2019 |
|
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
|
01 August 2019 |
|
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek
|
18 June 2019 |
|
FDA grants Roche's Polivy accelerated approval for people with previously treated aggressive lymphoma
|
13 June 2019 |
|
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
|
20 May 2019 |
|
Roche reports a strong start in 2019 and raises the outlook for the full-year
|
18 April 2019 |
|
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
|
20 March 2019 |
|
Roche enters into definitive merger agreement to acquire Spark Therapeutics
|
26 February 2019 |
|
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
|
21 January 2019 |
|
FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
|
06 December 2018 |
|
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
|
25 October 2018 |
|
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
|
22 August 2018 |
|
Roche reports very strong performance in the first half of 2018
|
26 July 2018 |
|
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
|
19 July 2018 |
|
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
|
02 July 2018 |